Foghorn Therapeutics Inc. (FHTX) Earnings Call Transcripts

Foghorn Therapeutics Inc.'s Latest Earnings Call - June 9, 2026

In Q2 2026, Foghorn Therapeutics Inc. focused on its strategic priorities, particularly the FHD-909 program, a selective SMARCA2 inhibitor in collaboration with Eli Lilly. The company maintained its guidance, with a decision on the program's expansion expected by summer. Revenue and earnings specifics were not disclosed, and there were no changes in guidance. The company's cash position stands at $184 million, with a runway into the first half of 2028, assuming continued collaboration with Lilly.

Reported metrics

Guidance from management

Guidance was maintained, with a decision on the FHD-909 program expected by summer. Cash runway is projected into the first half of 2028, contingent on the Lilly collaboration.

What management said

Right. So, my understanding, at least sort of in the United States is if you have lung cancer and you get a biopsy, this is just part of the standard NGS panel that's run. So as an example, the SMARCA4 mutations are in the Foundation screening and Tempus, et cetera. So, finding out whether you have a SMARCA4 mutation seems very readily accessible and available, especially in this day and age. The second part of your ...

What analysts pressed on

Analysts expressed concerns about the unmet need in non-small cell lung cancer and the potential efficacy of the FHD-909 program. Questions focused on the selectivity of SMARCA2 inhibitors and the implications for patient outcomes.

Main topics on the call

• FHD-909 Program — The FHD-909 program, a selective SMARCA2 inhibitor, is in collaboration with Eli Lilly. A decision on expansion is expected over the summer, with management stating, 'I believe we'll have enough non-small cell lung cance...
• Proprietary Pipeline — Foghorn's proprietary pipeline includes a CBP selective degrader for ER-positive breast cancer and a selective EP300 degrader for heme malignancies. Management highlighted progress towards potential IND filings in 2027.
• SMARCA2 Inhibitor Selectivity — The company emphasized the importance of selectivity in targeting SMARCA2 over SMARCA4 to avoid tolerability issues, stating, 'The setup here is to try and make sure you're only drugging or being more selective for SMARC...
• Non-Oncology Expansion — Foghorn is exploring applications in autoimmune disorders, with an undisclosed I&I asset showing promising results in animal models.

Read the full Foghorn Therapeutics Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 5 Foghorn Therapeutics Inc. earnings call transcripts on record, spanning April 9, 2024 to June 9, 2026. Based on this history, Foghorn Therapeutics Inc. reports semi-annually. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

FHTX

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

5

First call

April 9, 2024

Most recent

June 9, 2026

Reporting cadence

semi-annually